T Cell Density as a Predictor for Rectal Cancer Treatment Response
Author Information
Author(s): Yasuda Koji, Nirei Takako, Sunami Eiji, Nagawa Hirokazu, Kitayama Joji
Primary Institution: University of Tokyo
Hypothesis
The density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can predict the pathological response to chemoradiotherapy for rectal cancer.
Conclusion
The density of T lymphocytes in biopsy samples before treatment can predict how well rectal cancer patients will respond to chemoradiotherapy.
Supporting Evidence
- Higher densities of CD4(+) and CD8(+) T cells were associated with better tumor response to treatment.
- The study found that CD8(+) T cell density was an independent prognostic factor for complete response.
- Patients with low TIL may benefit from alternative treatments instead of standard chemotherapy.
Takeaway
Doctors can look at the number of certain immune cells in a biopsy to guess how well a patient with rectal cancer will respond to treatment.
Methodology
The study examined the density of CD4(+) and CD8(+) T cells in biopsy samples from rectal cancer patients before chemoradiotherapy and correlated these densities with tumor response.
Potential Biases
Potential bias in patient selection and retrospective analysis.
Limitations
The study is retrospective and may not account for all variables affecting treatment response.
Participant Demographics
Patients with rectal adenocarcinoma who received preoperative chemoradiotherapy.
Statistical Information
P-Value
0.0013, 0.0020
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website